查看文章

Materials and methods

Sixty patients diagnosed with MS and NDO were evaluated. All had received treatment with solifenacin 10 mg/daily for 3 months and were displeased with the results. Patients were divided in four groups. In Group A (n= 15) patients continued receiving solifenacin 10 mg/daily; in Group B (n= 15) patients received mirabegron 50 mg/daily; in Group C (n= 15) patients received desmopressin 120 mcg/daily and in Group D (n= 15) patients received mirabegron 50 mg/daily and desmopressin 120 mcg/daily. All patients were assessed with a 3 day bladder diary at the beginning and at the end of the treatment.

Results

All patients in Groups A, B and C did not demonstrate statistically significant changes at the end of the treatment period in their 3 day bladder diary and in the presence of urinary infections. In Group D, a statistically significant improvement was noted in the mean change from baseline to end of treatment in micturition episodes (3.5+/-0.4 micturition/24h), in urgency episodes (2.3+/-0.2) and mean number of urinary incontinence (1.0+/-0.2 episodes/24h).

Conclusions

Treatment with mirabegron and desmopressin revealed both effectiveness and safety in patients with NDO and MS.